At present, the research on the pathological process of BC bone metastasis has enabled the development and application of two bone improvement drugs for bone metastasis, namely the third-generation bisphosphonate and humanized anti-RANKL antibody (Maruthanila et al., 2017). The gene discussed is TNFSF11; the disease is breast cancer.